Europe Medical Cannabis to Reach $13 Billion by 2034, IMARC Group Reports

NEW YORK – A fresh industry report highlights substantial potential in Europe’s regulated medical Cannabis market as more countries refine access rules and patient numbers climb. The analysis from IMARC Group points to steady expansion driven by policy shifts and clinical demand, offering a snapshot of where the sector stands today.

Germany remains the clear leader, with simplified prescribing and broader insurance pathways fueling prescriptions. Patient numbers have risen sharply since Cannabis was removed from restrictive narcotics lists, and domestic production is scaling up alongside imports. Companies like Aurora Cannabis, Tilray, and Canopy Growth have launched new strains and delivery formats tailored to the German market, including locally grown options and premium flower products.

Other nations are moving at different speeds. The United Kingdom has expanded access through specialist clinics and telehealth, while Spain has taken steps toward regulated dispensing for certain conditions. Innovations in delivery systems, such as certified inhalation devices, aim to give doctors and patients more precise and consistent options beyond traditional oils and capsules.

According to the IMARC analysis, the European medical Cannabis market stood at approximately $3.06 billion in 2025 and is projected to reach $13.16 billion by 2034, expanding at a CAGR of 17.6% between 2026 and 2034. Indica varieties held the largest share by species last year, while CBD-led products accounted for over half the market by derivative. Cancer-related applications made up the biggest use case, reflecting the role of Cannabis in managing pain, nausea, and appetite issues during treatment. Oral formats like solutions and capsules led in administration methods.

These figures sit alongside other estimates that vary based on methodology and scope. Some broader projections for Europe’s legal Cannabis sector, including potential adult-use elements in pilot programs, point to even larger numbers in the coming decade, though medical channels continue to form the regulated core.

The IMARC report identifies several growth drivers: increasing legalization, expanding therapeutic applications, rising patient demand, technological advances in cultivation and extraction, and growing R&D investment. Oral solutions and capsules dominate product formats, holding 55.2% of European market share, reflecting the continent’s pharmaceutical-style approach to Cannabis delivery.

That pharmaceutical orientation is also shaping competitive dynamics. Licensed operators that can meet strict EU-GMP standards are gaining a major competitive advantage, and institutional investors are beginning to take notice. The barrier to entry is high, and intentionally so.

The European medical Cannabis market is maturing in a way that the North American market did not. Rather than racing toward retail scale, European regulators have kept the framework pharmaceutical in character, prioritizing clinical validation, supply chain compliance, and patient safety. That discipline has slowed early-stage market entry but is now generating something more durable: a credentialed industry with institutional backing and genuine reimbursement pathways.

The IMARC projections are not speculative. They are the downstream consequence of policy choices already made. Germany proved the demand is there. France confirmed the model can be replicated. The remaining question for the decade is not whether the European market grows – it will – but which operators, countries, and supply chains capture the value when it does.